This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.

Sarepta Shares Still Have Upside
Sarepta Shares Still Have Upside

10/03/12 - 10:43 AM EDT

Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.

Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302

A New Reason to be Bullish About Sarepta Therapeutics

A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.

Idenix Pharma: Guilty By Association
Idenix Pharma: Guilty By Association

09/21/12 - 07:48 AM EDT

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

Bull Case on Peregrine Pharma Shouldn't Be Dismissed

Believers in Peregrine's lung cancer drug bavituximab state their case.

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

More Reasons to Invest in Sarepta With Caution

Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.

Sarepta's Risks Shouldn't Be Ignored
Sarepta's Risks Shouldn't Be Ignored

08/21/12 - 07:00 AM EDT

There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.

In These Turbulent Times, Reach for Merck

The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.

Page 2 of 5
Top Rated Stocks Top Rated Funds Top Rated ETFs